Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.54 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.48 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.42 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.40 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 6/20 | 0.39 |
| ▸ | FNTB | P49356 | 6/20 | 0.39 |
| ▸ | PGGT1B | P53609 | 5/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818717 | 1.00 | NOD1 (0.54) | NOD1C3AR1FOLH1CTDSP1GNPAT | |
| SCHEMBL30193452 | 0.97 | NOD1 (0.52) | NOD1C3AR1FOLH1CTDSP1GNPAT | |
| SCHEMBL30193317 | 0.94 | NOD1 (0.50) | NOD1C3AR1FOLH1CTDSP1GNPAT | |
| SCHEMBL1711378 | 0.92 | NOD1 (0.48) | NOD1C3AR1FOLH1 | |
| SCHEMBL29360312 | 0.92 | NOD1 (0.48) | NOD1C3AR1FOLH1CTDSP1GNPAT | |
| SCHEMBL1711946 | 0.92 | NOD1 (0.48) | NOD1C3AR1FOLH1 | |
| SCHEMBL24804881 | 0.89 | C3AR1 (0.49) | NOD1C3AR1FOLH1CTDSP1GNPAT | |
| SCHEMBL5598692 | 0.88 | NOD1 (0.52) | NOD1C3AR1FOLH1GNPAT | |
| SCHEMBL6047671 | 0.88 | C3AR1 (0.46) | NOD1C3AR1FOLH1CTDSP1GNPAT | |
| SCHEMBL16862522 | 0.88 | C3AR1 (0.46) | NOD1C3AR1FOLH1CTDSP1GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | claimed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | claimed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | claimed |
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2942059-A1 | 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Biokine Therapeutics LTD. (IL) | 2015-11-11 | — | — | EP | disclosed |
| US-9034814-B2 | CXCR4 antagonists for wound healing and re-epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2015-05-19 | — | — | US | disclosed |
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2015-05-07 | — | — | US | disclosed |
| US-20100184694-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY | BIOKINE THERAPEUTICS LTD. (IL) | 2010-07-22 | — | — | US | disclosed |
| US-20100166715-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | BIOKINE THERAPEUTICS LTD. (IL) | 2010-07-01 | — | — | US | disclosed |
| US-20100143334-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | BIOKINE THERAPEUTICS LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2010-03-04 | — | — | US | disclosed |
| US-7595298-B2 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2009-09-29 | — | — | US | disclosed |
| US-20060264605-A1 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-23 | — | — | US | disclosed |
| US-7138488-B2 | Polypeptides having anti-HIV activity and compositions comprising same | BIOKINE THERAPEUTICS LTD. (IL) | 2006-11-21 | — | — | US | disclosed |
| US-20040116655-A1 | Novel polypeptides and anti-hiv drugs containing the same | BIOKINE THERAPEUTICS LTD. (IL) | 2004-06-17 | — | — | US | disclosed |
| EP-1323730-A1 | NOVEL POLYPEPTIDES AND ANTI-HIV DRUGS CONTAINING THE SAME | SEIKAGAKU CORPORATION (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100055088-A1 | CXCR4 Antagonists for Wound Healing and Re-Epithelialization | CXCR4, CXCL12, CXCR5 | NOD1 2996/4885C3AR1 77/4885FOLH1 3082/4885 |
| US-20100143334-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | CXCR5, CXCR4, CXCR1 | NOD1 891/4885C3AR1 55/4885FOLH1 2278/4885 |
| US-20100184694-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY | CXCR4, CXCR5, CXCR1 | NOD1 2750/4885C3AR1 102/4885FOLH1 1047/4885 |
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | NGLY1, VIP, TAP1 | NOD1 4232/4885C3AR1 2907/4885FOLH1 158/4885 |
| US-20100166715-A1 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | CXCR4, CXCL12, CXCR1 | NOD1 2486/4885C3AR1 138/4885FOLH1 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.